{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-26-013527","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2026-06-25T22:49:24+00:00","discovered_at":"2026-06-26T10:05:00.291241+00:00","generated_at":"2026-06-26T10:05:55.234512+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Bio-Techne to be acquired by Merck KGaA for $73.00 per share in all-cash deal","bullets":["Merck KGaA to acquire Bio-Techne (TECH) for $73.00 per share in cash.","Termination fees: Company pays $230.5M for superior proposal; Parent pays $576.1M for antitrust failure.","Retention bonuses: CEO Kelderman $2.12M, CFO Hippel $1.54M, plus Geist $1.16M, Bohnen $0.97M, Crouse $0.91M.","Closing requires shareholder approval, HSR and antitrust clearances; outside date Mar 25, 2027, extendable.","Board unanimously recommends the merger; subject to no-shop and fiduciary-out provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-013527","json":"https://secwatch.observer/filing/0001999371-26-013527.json","markdown":"https://secwatch.observer/filing/0001999371-26-013527.md","text":"https://secwatch.observer/filing/0001999371-26-013527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000199937126013527/0001999371-26-013527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000199937126013527/tech-8k_062326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T10:05:55.234512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}